Skip to content

Monoclonal antibody drugs raise hopes for keeping high-risk COVID-19 patients out of the hospital. But it’s complicated.

There is a need for therapies for mild to moderate COVID-19. It's not clear how much monoclonal antibodies can fill the gap.

In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis.
In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis.Read moreDavid Morrison / AP